Respuesta a Eltrombopag en pacientes pediátricos con Trombocitopenia inmune primaria crónica en dos instituciones de Barranquilla en el periodo 2021-2022
Cargando...
Fecha
2023
Autores
Domínguez Charris, Martha Ligia
Título de la revista
ISSN de la revista
Título del volumen
Editor
Ediciones Universidad Simón Bolívar
Facultad de Ciencias de la Salud
Facultad de Ciencias de la Salud
Resumen
Los pacientes con trombocitopenia inmune primaria (PTI) se
caracterizan por presentar disminución del recuento de plaquetas y dependiendo el
número de las mismas pueden presentarse un número variable de manifestaciones
clínicas. Esta enfermedad es considerada benigna y autolimitada que suele resolver
en el 60% de los pacientes en los primeros 6 meses; sin embargo existe un grupo
de paciente en el cual se cronifica, en estos se aplican tratamientos como los
corticoides e infusiones de inmunoglobulina G, sin embargo ante la persistencia de
la trombocitopenia se han ampliado las opciones de tratamiento con el uso de
medicamentos agonistas del receptor de la trombopoyetina (r-TPO) (Eltrombopag)
Objetivo: Evaluar la respuesta al Eltrombopag en pacientes pediátricos
diagnosticados con trombocitopenia inmunológica primaria (PTI) crónica a través
del recuento de plaquetas en dos centros de consulta externa de Barranquilla
durante el periodo 2021-2022.
Metodología : Estudio observacional de cohorte retrospectivo en dos centros, con
la obtención de historias ciencias que confieran al diagnostico de trombocitopenia
inmune primaria dados por el CIE10 y cumplan con los criterios de inclusión
establecidos para la investigación.
Patients with primary immune thrombocytopenia (ITP) are characterized by a decrease in platelet count and depending on the number of platelets, a variable number of clinical manifestations may occur. This disease is considered benign and self-limited and usually resolves in 60% of patients in the first 6 months; however there is a group of patients in which it becomes chronic, in these patients treatments such as corticosteroids and immunoglobulin G infusions are applied; however, in view of the persistence of thrombocytopenia, the treatment options have been expanded with the use of thrombopoietin receptor agonist drugs (r-TPO) (Eltrombopag). Objective : To evaluate the response to Eltrombopag in pediatric patients diagnosed with chronic primary immune thrombocytopenia (ITP) through platelet counts in two outpatient centers in Barranquilla during the period 2021-2022. Methodology: Observational study of restrospective cohort in two centers, with the collection of clinical histories that confer the diagnosis of primary immune thrombocytopenia given by the ICD10 and meet the inclusion criteria established for the research.
Patients with primary immune thrombocytopenia (ITP) are characterized by a decrease in platelet count and depending on the number of platelets, a variable number of clinical manifestations may occur. This disease is considered benign and self-limited and usually resolves in 60% of patients in the first 6 months; however there is a group of patients in which it becomes chronic, in these patients treatments such as corticosteroids and immunoglobulin G infusions are applied; however, in view of the persistence of thrombocytopenia, the treatment options have been expanded with the use of thrombopoietin receptor agonist drugs (r-TPO) (Eltrombopag). Objective : To evaluate the response to Eltrombopag in pediatric patients diagnosed with chronic primary immune thrombocytopenia (ITP) through platelet counts in two outpatient centers in Barranquilla during the period 2021-2022. Methodology: Observational study of restrospective cohort in two centers, with the collection of clinical histories that confer the diagnosis of primary immune thrombocytopenia given by the ICD10 and meet the inclusion criteria established for the research.
Descripción
Palabras clave
Agonista del receptor de la Trombopoyetina, Eltrombopag, Trombocitopenia inmunológica primaria crónica, Anticuerpos, Corticoides, Inmunoglobulina, Thrombopoietin receptor agonist, Chronic primary immune thrombocytopenia, Antibodies, Corticosteroids, Immunoglobulin
